Corline Biomedical AB (CLBIO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.072x

Based on the latest financial reports, Corline Biomedical AB (CLBIO) has a cash flow conversion efficiency ratio of -0.072x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.76 Million ≈ $-727.59K USD) by net assets (Skr93.76 Million ≈ $10.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Corline Biomedical AB net asset quality index to measure how much of total assets are equity-financed.

Corline Biomedical AB - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Corline Biomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Corline Biomedical AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Corline Biomedical AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Corline Biomedical AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Mereo BioPharma Group PLC ADR NASDAQ:MREO	-0.127x
Analabs Resources Bhd KLSE:7083	-0.013x
Vinyl Chemicals (India) Limited NSE:VINYLINDIA	-0.462x
Chia Her Industrial Co Ltd TW:1449	-0.040x
ActRO Co. Ltd KQ:290740	-0.024x
Cytogen Inc KQ:217330	-0.059x
Maison Antoine Baud Société Anonyme PA:MLMAB	N/A
Taiwan Alpha Electronic Co Ltd TWO:6204	0.009x

Annual Cash Flow Conversion Efficiency for Corline Biomedical AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Corline Biomedical AB market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr93.76 Million ≈ $10.09 Million	Skr-17.69 Million ≈ $-1.90 Million	-0.189x	-89.81%
2024-12-31	Skr86.91 Million ≈ $9.35 Million	Skr-8.64 Million ≈ $-929.69K	-0.099x	-1146.88%
2023-12-31	Skr93.32 Million ≈ $10.04 Million	Skr886.00K ≈ $95.35K	0.009x	+113.92%
2022-12-31	Skr94.59 Million ≈ $10.18 Million	Skr-6.45 Million ≈ $-694.34K	-0.068x	-30.12%
2021-12-31	Skr92.23 Million ≈ $9.93 Million	Skr-4.83 Million ≈ $-520.32K	-0.052x	+46.16%
2020-12-31	Skr52.03 Million ≈ $5.60 Million	Skr-5.07 Million ≈ $-545.18K	-0.097x	+58.27%
2019-12-31	Skr59.32 Million ≈ $6.38 Million	Skr-13.84 Million ≈ $-1.49 Million	-0.233x	-212.44%
2018-12-31	Skr54.96 Million ≈ $5.91 Million	Skr-4.10 Million ≈ $-441.66K	-0.075x	+31.11%
2017-12-31	Skr45.93 Million ≈ $4.94 Million	Skr-4.98 Million ≈ $-535.71K	-0.108x	+41.76%
2016-12-31	Skr38.75 Million ≈ $4.17 Million	Skr-7.21 Million ≈ $-776.02K	-0.186x	+6.53%
2015-12-31	Skr21.25 Million ≈ $2.29 Million	Skr-4.23 Million ≈ $-455.34K	-0.199x	+52.91%
2014-12-31	Skr5.48 Million ≈ $590.25K	Skr-2.32 Million ≈ $-249.55K	-0.423x	-22.53%
2013-12-31	Skr8.00 Million ≈ $860.60K	Skr-2.76 Million ≈ $-296.95K	-0.345x	--

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$48.79 Million

Skr453.36 Million SEK

Market Cap Rank

#21933 Global

#411 in Sweden

Share Price

Skr17.70

Change (1 day)

+1.14%

52-Week Range

Skr11.80 - Skr21.20

All Time High

Skr28.20